Rigerna Bio Secures Over RMB 200 Million in Pre-A Financing to Advance First-in-Class siRNA Therapies for Kidney and Metabolic Diseases

VCBeat learned第一时间: On March 20, 2026, Rigerna, a clinical-stage small nucleic acid drug company, announced the completion of a Pre-A round of financing exceeding 200 million yuan, led by Bayland Capital. Delian Capital, Huatai Genscript Fund, Jinyi Fuxin, SEALAND INNOVATION CAPITAL CO.,LTD, Legend Capital, and existing shareholder Yuanxi Haihe (Tianjin) Biomedical Industry Fund Partnership (Limited Partnership) participated in this round of investment.

Since its establishment in 2022, Rigerna has been committed to innovation-driven development, focusing on the fields of kidney and metabolic diseases, and striving to become a leader and transformer in the small nucleic acid pharmaceuticals sector. With forward-looking strategies, its leading pipeline has entered Phase II clinical trials and is expected to become the world’s first approved small nucleic acid drug for IgA nephropathy. To address unmet clinical needs in kidney and metabolic diseases, Rigerna is developing multiple First-in-class pipelines, building a multi-layered and well-structured pipeline matrix. The completion of this round of financing and the advancement of various BD collaborations have provided the company with sufficient cash reserves, laying a solid foundation for future growth. The company is now sincerely inviting more outstanding talents to join.

Rigerna Founder Dr. Huang Yuanyu:"Sincerely thank all new and existing shareholders for their trust and unwavering support in Rigerna! The successful completion of this round of financing not only provides a solid financial foundation for the company's innovative development but also injects strong momentum into its future rapid growth. Adhering to its original aspirations and strategic positioning, the company will fully advance Rigerna into a new stage of development. Driven by innovation, it will continuously break through the extrahepatic delivery bottleneck, build proprietary technology and pipelines, accelerate clinical translation and clinical development, and achieve the commercialization of innovative small nucleic acid drugs as soon as possible to benefit patients worldwide."

Bayland Capital："Kidney disease is not only a global challenge but also a field that fosters the development of groundbreaking drugs. We are thrilled to see Rigerna making significant breakthroughs in this area. The company’s leading pipeline for IgA nephropathy is at the forefront globally, and its reserve technologies demonstrate potential for targeting different types of kidney cells. Looking ahead, we are excited to collaborate with Rigerna to develop more First-in-class small nucleic acid drugs for kidney diseases, benefiting 800 million patients worldwide."

Delian Capital："With the continuous breakthroughs in delivery technology and drug development, siRNA drugs, with their high specificity, long-lasting effects, and broad application potential, have entered a golden era of commercial realization and rapid pipeline expansion. Rigerna's core team has been deeply engaged in the siRNA field for many years, boasting a complete R&D system, outstanding execution efficiency, and organizational effectiveness. Leveraging original innovation, the company has built a differentiated product pipeline with clear clinical value. The lead pipeline is progressing rapidly and is expected to become the world’s first siRNA therapy for IgA nephropathy to enter pivotal clinical trials. Meanwhile, significant breakthroughs have been achieved in cutting-edge areas such as kidney-targeted delivery and dual-target siRNA, with multiple projects about to enter clinical stages. In its financing rounds, the company has attracted several leading industry investors, achieving a high degree of synergy in industrial resources. We look forward to Suzhou Rigerna Therapeutics, with original innovation as its foundation and clinical value at its core, jointly leading small nucleic acid drugs into the 2.0 era."

Hua Tai Genscript Fund:"Rigerna is a highly promising innovator in the small nucleic acid赛道. The company's core team has over a decade of deep cultivation, not only possessing solid底层技术accumulation but also demonstrating profound insights into clinical needs and efficient execution. We are optimistic about Rigerna's breakthrough progress in肝外targeted delivery technology and the broad application prospects of its existing pipeline in complement-mediated diseases. We look forward to Rigerna's continued深耕in the small nucleic acid drug field, bringing innovative therapies to patients worldwide as soon as possible and becoming a benchmark enterprise for Chinese innovative drugs going global."

Jinyi Fu Xin:"Since its establishment, Rigerna has made impressive R&D progress, fully demonstrating the team's outstanding foresight and execution capabilities. Rigerna is one of the few global innovators to have built a 'general formula' modification technology platform and broken through the extrahepatic delivery technology barriers with multiple exclusive strategies. Its gradient-differentiated pipeline layout in chronic diseases such as kidney disease and cardiovascular diseases not only reflects a precise grasp of unmet clinical needs but also validates the complete path from technology development to industrial transformation. We look forward to Rigerna ushering in a new era of nucleic acid drug therapies."

SEALAND INNOVATION CAPITAL CO.,LTD:"Rigerna has built a differentiated pipeline in the fields of kidney disease and metabolic diseases by leveraging its globally scarce general modification and extrahepatic delivery platform, demonstrating strong innovation capabilities and global competitiveness. We highly recognize the professionalism and strategic vision of the team, and it is a great honor to participate in this round of financing, which will support the team in accelerating pipeline advancement and clinical translation, safeguarding life and health with innovative outcomes."

Legend Capital:"The small nucleic acid drug track is currently entering a period of rapid expansion following technological breakthroughs, with market potential continuously growing. Rigerna, with its forward-looking strategic layout and efficient R&D execution, has built a multi-level progressive pipeline matrix. Its lead pipeline is among the global first-tier, while it continues to make breakthroughs in cutting-edge technology fields such as kidney-targeted delivery, showcasing strong innovation capabilities and global competitiveness. Legend Capital highly values the industrial transformation brought by frontier biotechnology and is very pleased to partner with Rigerna. We will actively empower the company in areas such as advanced technology integration, industrial synergy, and international market expansion, jointly promoting China-originated siRNA drugs to the world, safeguarding the health and lives of patients globally through source innovation."

Yuanxi Haihe:"We are honored to continue participating in Rigerna's current round of financing as existing shareholders. Over the past year, we have been delighted to witness significant progress made by the company: it has successfully transitioned from a preclinical-stage company to a biotech firm in the mid-to-late clinical stage; its globally innovative lead pipeline has entered Phase II clinical trials, with development progress ranking among the global leaders, demonstrating strong potential in preclinical and early clinical data. Meanwhile, the company has achieved critical NHP validation data for its extrahepatic delivery (especially renal targeting) technology platform and has established multiple forward-looking BD collaborations with various enterprises, fully demonstrating the value of its platform technology and the business development capabilities of its team. We believe that as the lead pipeline obtains proof-of-concept data and the value of the extrahepatic delivery platform continues to be unlocked, Rigerna is well-positioned to become a leading player in the small nucleic acid drug field. We remain optimistic about the company’s innovative efforts in areas of significant unmet clinical needs and will continue to support its growth as always."

Contact for collaboration: Dr. Ma (E-mail: mma@rigerna.com)

Bayland Capital (Beijing) Co., Ltd. was established in 2019 as a professional private equity investment management institution. Bayland Capital, the sole investment platform of Pharmaron, relies on Pharmaron's strong industry background and focuses on equity investments in the biopharmaceutical field. With a unique industry perspective, Bayland Capital pays attention to globally leading new drug R&D service providers, technological innovation platforms, biotechnology companies, and medical device companies, striving to become a trusted long-term partner and a bridge connecting life sciences, healthcare industries, and capital.

Delian Capital, established in 2011, has always focused on technology and innovative healthcare. It emphasizes sub-sectors such as semiconductor-related technologies, energy technology, intelligent equipment, artificial intelligence, innovative drugs, and medical technology, seeking early-stage investment opportunities driven by technological innovation. It has invested in over a hundred projects, including: SinoPower Technologies, Anqiwei, Nanjing Hongtai, Intron Advanced Technology, Rock Robot, Mech-Mind Robotics, Fit2Cloud, Venus Medtech, Amunix, Core Medical, Orange Sail Pharmaceuticals, and SeekGene.

HT Jinsirui Fund is jointly established by HT Zijin and Genscript. HT Zijin, a wholly-owned subsidiary of Huatai Securities (601688.SH) that engages in private equity investment business, leverages the full business chain advantages of Huatai Securities to provide comprehensive capital services to its partners. The company manages assets exceeding 60 billion yuan and operates multiple funds including PE, M&A, FOF, and industry-focused funds. Genscript Biotech (HK.1548) is a global leader in life sciences R&D and production services. Rooted in solid DNA synthesis technology, Genscript has established four major business units: life sciences services and products, biologics contract development and manufacturing (CDMO), industrial synthetic products, and cell therapy. Collaborating with partners, Genscript accelerates scientific discoveries and breakthroughs in therapies. Its operations span over 100 countries and regions worldwide, serving more than 200,000 customers with high-quality services and products.

Wuxi Jinyifu New Biomedical Venture Capital Partnership (Limited Partnership), established in May 2024, is located in Huishan District, Wuxi City. It is an industrial fund jointly funded by Wuxi Innovation Investment Group Co., Ltd., Jiangsu Yuanli Industrial Investment Co., Ltd., and Beijing Joinn Laboratories (China) Co., Ltd. With a fund size of 1 billion RMB, it primarily invests in areas such as biomedicine, life sciences, significant unmet clinical needs, innovative breakthrough technologies, medical devices, and CROs (Contract Research Organizations) within the life and health sector. The Jinyifu New Fund aims to leverage Wuxi’s strong foundation in the biomedical industry to integrate advantageous resources across the industrial chain through professional investment operations. Its goal is to create a globally competitive biopharmaceutical industry cluster while comprehensively promoting the high-quality development of Wuxi’s biomedical industry.

SEALAND INNOVATION CAPITAL CO.,LTD is a leading private equity fund management subsidiary of securities companies in China and a platform under Guohai Securities for private equity investment fund business. It has been consecutively ranked among the top ten private equity fund management institutions of securities companies in China and the top 100 best private equity investment institutions from 2019 to 2025. SEALAND INNOVATION CAPITAL CO.,LTD initiates, establishes, and manages multiple primary and quasi-primary private equity investment funds, including private placement and block trading equity investment funds of listed companies, growth-stage equity investment funds, industry-themed investment funds, mezzanine buyout funds, and S-strategy funds. The total scale of managed assets exceeds 21.4 billion yuan.

SEALAND INNOVATION CAPITAL CO.,LTD gathers top talents and has a professional investment team composed of individuals with industry backgrounds as well as expertise in investment banking, law, and accounting. Centered around the two main themes of "technological innovation" and "healthy living," the company focuses on investing in strategic emerging and modern industries such as healthcare, new energy, new materials, next-generation information technology, and aerospace. It has invested in over a hundred leading enterprises in various sub-industries. Adhering to the investment philosophy of rigorousness, pragmatism, value investing, and win-win cooperation, SEALAND INNOVATION CAPITAL provides comprehensive capital market operations and value-added services to its portfolio companies, supporting their growth while delivering long-term, stable, and high-quality returns to shareholders and investors.

Lenovo Capital and Incubator Group (LCIG), established in 2016, is a global technology industry fund under Lenovo Group. It aims to integrate Lenovo's global resources and use investment and incubation as tools to lay out the future of technology. Lenovo Capital has invested in over 300 outstanding companies, utilizing an innovative CVC 2.0 model to fully leverage Lenovo's global brand, channels, supply chain, and other industrial advantages. It builds a bridge for business cooperation between its portfolio companies and Lenovo Group, promoting the implementation of cutting-edge technologies in the industry and establishing a mutually complementary and closely linked ecosystem for shared success.

Yuanxi Haihe (Tianjin) Biomedical Industry Fund Partnership (Limited Partnership), established through the collaboration between CanSinoBIO and GSR Ventures, aims to jointly create and maintain an innovative and synergistic biopharmaceutical ecosystem. Rooted in the industry and serving the industry, it promotes the coordinated development of capital and industry with a win-win attitude. By integrating the extensive industry resources and professional investment management experience of CanSinoBIO and GSR Ventures, we believe this partnership will bring more opportunities and innovation to the biopharmaceutical industry, advance medical technology, and contribute to the cause of human health.